Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. Its products are primarily catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 2000 and is headquartered in St. Paul, MN.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorMedical
Phone651-259-1600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$217.04 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems Inc (NASDAQ:CSII) released its earnings results on Wednesday, January, 30th. The medical device company reported $0.01 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.05. The medical device company had revenue of $60.21 million for the quarter, compared to analyst estimates of $59.66 million. Cardiovascular Systems had a net margin of 0.74% and a return on equity of 1.28%. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What guidance has Cardiovascular Systems issued on next quarter's earnings?
Cardiovascular Systems updated its FY 2019 earnings guidance on Wednesday, January, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $243-247 million, compared to the consensus revenue estimate of $244.95 million.
What price target have analysts set for CSII?
4 equities research analysts have issued 1-year target prices for Cardiovascular Systems' shares. Their predictions range from $45.00 to $50.00. On average, they anticipate Cardiovascular Systems' share price to reach $47.50 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Cardiovascular Systems.
What is the consensus analysts' recommendation for Cardiovascular Systems?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems exited second-quarter fiscal 2019 with earnings beat and in line revenues. The company witnessed year-over-year increase in the Coronary and peripheral device segments. Cardiovascular Systems continued to see higher revenues from Atherectomy franchises, growing international sales of OAS and top-line contributions from the emerging product pipeline. We are also upbeat about the company’s recent announcement of the first global use of Diamondback 360 Coronary OAS in UAE. Further, the company is progressing with the international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside the United States and Japan. In the past three months, Cardiovascular Systems has outperformed the industry. On the flip side, the company faces cut-throat competition in the niche space. Further, its failure to enter global markets might affect results. " (3/15/2019)
- 2. Needham & Company LLC analysts commented, "CSII’s F1Q19 revenue beat while EPS missed consensus and management maintained FY19 revenue guidance. While CSII should continue to benefit from the Japanese launch, an exclusive international distribution agreement (OrbusNeich), new support products, and building rep productivity, we believe there is execution risk in CSII’s long-term transformation (see our analyst meeting note here). Given these points, increasingly difficult comps in FY19, and our belief that CSII shares are fairly valued, we maintain our Hold rating." (10/31/2018)
Has Cardiovascular Systems been receiving favorable news coverage?
Media coverage about CSII stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cardiovascular Systems earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Are investors shorting Cardiovascular Systems?
Cardiovascular Systems saw a decline in short interest in the month of February. As of February 28th, there was short interest totalling 865,738 shares, a decline of 32.3% from the February 15th total of 1,279,246 shares. Based on an average daily trading volume, of 240,615 shares, the days-to-cover ratio is presently 3.6 days. Approximately 2.6% of the shares of the stock are short sold. View Cardiovascular Systems' Current Options Chain.
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include athenahealth (ATHN), NMC Health (NMC), Ascendis Pharma A/S (ASND), Penumbra (PEN), DiaSorin (DSRLF), Hikma Pharmaceuticals (HKMPF), Alkermes (ALKS), Chemed (CHE), Array Biopharma (ARRY), Healthequity (HQY), Patheon (PTHN), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Cronos Group (CRON) and GW Pharmaceuticals PLC- (GWPH).
What other stocks do shareholders of Cardiovascular Systems own?
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Scott R. Ward, Chairman, President & Chief Executive Officer
- Rhonda J. Robb, Chief Operating Officer
- Jeffrey S. Points, CFO & Principal Accounting Officer
- Ryan D. Egeland, Vice President-Medical Affairs
- Sandra M. Sedo, Chief Compliance Officer
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.33%), Partner Fund Management L.P. (4.59%), D. E. Shaw & Co. Inc. (2.40%), Frontier Capital Management Co. LLC (2.05%), New York State Common Retirement Fund (1.51%) and Norges Bank (1.44%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Martha Goldberg Aronson, Sandra Sedo and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Which institutional investors are selling Cardiovascular Systems stock?
CSII stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, Acadian Asset Management LLC, Frontier Capital Management Co. LLC, Meeder Asset Management Inc., Bank of America Corp DE, FMR LLC and GW&K Investment Management LLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, Jeffrey S Points and Sandra Sedo. View Insider Buying and Selling for Cardiovascular Systems.
Which institutional investors are buying Cardiovascular Systems stock?
CSII stock was bought by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Norges Bank, BlackRock Inc., Sectoral Asset Management Inc, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, First Trust Advisors LP and Hsbc Holdings PLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Martha Goldberg Aronson and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $39.6550.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $1.38 billion and generates $217.04 million in revenue each year. The medical device company earns $1.71 million in net income (profit) each year or $0.05 on an earnings per share basis.
What is Cardiovascular Systems' official website?
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
